194 related articles for article (PubMed ID: 28703780)
1. In Vitro and In Vivo Control of Secondary Bacterial Infection Caused by Leishmania major.
Yehia HM; Al-Olayan EM; El-Khadragy MF; Metwally DM
Int J Environ Res Public Health; 2017 Jul; 14(7):. PubMed ID: 28703780
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of difloxacin against canine bacterial isolates.
van den Hoven R; Wagenaar JA; Walker RD
J Vet Diagn Invest; 2000 May; 12(3):218-23. PubMed ID: 10826834
[TBL] [Abstract][Full Text] [Related]
3. Activity of newer fluoroquinolones against gram-positive and gram-negative bacteria isolated from ocular infections: an in vitro comparison.
Duggirala A; Joseph J; Sharma S; Nutheti R; Garg P; Das T
Indian J Ophthalmol; 2007; 55(1):15-9. PubMed ID: 17189881
[TBL] [Abstract][Full Text] [Related]
4. Bacterial spectrum and antimicrobial susceptibility patterns in acquired and connatal lacrimal duct stenosis.
Prokosch V; Prokosch JE; Promesberger J; Idelevich EA; Böhm MR; Thanos S; Stupp T
Curr Eye Res; 2014 Nov; 39(11):1069-75. PubMed ID: 24912091
[TBL] [Abstract][Full Text] [Related]
5. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones.
Alexandrakis G; Alfonso EC; Miller D
Ophthalmology; 2000 Aug; 107(8):1497-502. PubMed ID: 10919897
[TBL] [Abstract][Full Text] [Related]
6. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
Seifert H
Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
[TBL] [Abstract][Full Text] [Related]
7. Pattern of Polymicrobial Isolates and Antimicrobial Susceptibility from Blood.
Shabbir S; Jamil S; Hafiz S
J Coll Physicians Surg Pak; 2016 Jul; 26(7):585-8. PubMed ID: 27504550
[TBL] [Abstract][Full Text] [Related]
8. Microbiologic characteristics and antibiotic resistance rates of diabetic foot infections.
Pontes DG; Silva ITDCE; Fernandes JJ; Monteiro AFG; Gomes PHDS; Ferreira MGM; Lima FG; Correia JO; Santos NJND; Cavalcante LP
Rev Col Bras Cir; 2020; 47():e20202471. PubMed ID: 32667581
[TBL] [Abstract][Full Text] [Related]
9. Bacterial etiology of ocular and periocular infections, antimicrobial susceptibility profile and associated factors among patients attending eye unit of Shashemene comprehensive specialized hospital, Shashemene, Ethiopia.
Mohammed AA; Ali MM; Zenebe MH
BMC Ophthalmol; 2020 Mar; 20(1):124. PubMed ID: 32228528
[TBL] [Abstract][Full Text] [Related]
10. In vitro antibacterial activity of moxifloxacin against hospital isolates: a multicentre study.
Soussy CJ; Nguyen J; Goldstein F; Dabernat H; Andremont A; Leclercq R; Drugeon H; Cavallo P; Chardon H; Etienne J; Rio Y; Courvalin P
Clin Microbiol Infect; 2003 Oct; 9(10):997-1005. PubMed ID: 14616741
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and etiology of neonatal sepsis in Tikur Anbessa University Hospital, Ethiopia.
Shitaye D; Asrat D; Woldeamanuel Y; Worku B
Ethiop Med J; 2010 Jan; 48(1):11-21. PubMed ID: 20607993
[TBL] [Abstract][Full Text] [Related]
12. Anti-Leishmanial Activity (In Vitro and In Vivo) of Allicin and Allicin Cream Using Leishmania major (Sub-strain Zymowme LON4) and Balb/c Mice.
Metwally DM; Al-Olayan EM; El-Khadragy MF; Alkathiri B
PLoS One; 2016; 11(8):e0161296. PubMed ID: 27537199
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of 4903 bacterial isolates to gemifloxacin--an advanced fluoroquinolone.
Blondeau JM; Hansen G; Metzler KL; Borsos S; Irvine LB; Blanco L
Int J Antimicrob Agents; 2003 Aug; 22(2):147-54. PubMed ID: 12927955
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent.
Kwon AR; Min YH; Ryu JM; Choi DR; Shim MJ; Choi EC
J Antimicrob Chemother; 2006 Sep; 58(3):684-8. PubMed ID: 16873394
[TBL] [Abstract][Full Text] [Related]
15. Comparative antimicrobial susceptibility of aerobic and facultative bacteria from community-acquired bacteremia to ertapenem in Taiwan.
Lee SC; Huang SS; Lee CW; Fung CP; Lee N; Shieh WB; Siu LK
BMC Infect Dis; 2007 Jul; 7():79. PubMed ID: 17640342
[TBL] [Abstract][Full Text] [Related]
16. [In vitro activity of prulifloxacin, levofloxacin and ciprofloxacin against urinary pathogens].
Noviello S; Ianniello F; Leone S; Esposito S
Infez Med; 2006 Mar; 14(1):24-8. PubMed ID: 17405239
[TBL] [Abstract][Full Text] [Related]
17. [Nationwide sensitivity surveillance of ciprofloxacin and various parenteral antibiotics against bacteria isolated from patients with severe infections--the first Ciproxan IV special investigation in 2001].
Yamaguchi K; Ishii Y; Iinuma Y; Yamanaka K; Ichiyama S; Watanabe N; Uehara N; Kaku M; Kurokawa Y; Hayashi M; Hirakata Y
Jpn J Antibiot; 2003 Dec; 56(6):546-73. PubMed ID: 15007872
[TBL] [Abstract][Full Text] [Related]
18. Bacteraemia in a tertiary care urban hospital in south India.
Chaudhury A; Rao TV
Indian J Pathol Microbiol; 1999 Jul; 42(3):317-20. PubMed ID: 10862291
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
Rolston KV; Ho DH; LeBlanc B; Bodey GP
Chemotherapy; 1990; 36(5):365-72. PubMed ID: 2209169
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
